Table 5. Results of the multivariate Cox regression analysis for the QFS analysis of each targeted score of the QLQ-C30 for the raw and the weighed analysis.

			without IPW	with IPW
		N (events)	HR [CI 95%]	HR [CI 95%]
Global health status		63 (35)
arm a	(arm 2) vs.(arm 1)		0.86 [0.38–1.96]	0.58 [0.31–1.07]
number of metastatic sites	(2 or more) vs. 1		3.98 [1.21–13.71]	4.39 [2.03–9.49]
Interaction between arm and number of metastatic sites			0.38 [0.08–1.88]	0.41 [0.13–1.27]
Physical functioning		65 (36)
arm a	(arm 2) vs.(arm 1)		0.34 [0.14–0.82]	0.25 [0.13–0.48]
number of metastatic sites	(2 or more) vs. 1		2.80 [0.87–9.08]	2.71 [1.28–5.75]
Interaction between arm and number of metastatic sites			0.86 [0.18–4.16]	1.09 [0.36–3.30]
Emotional functioning		63 (37)
arm a	(arm 2) vs.(arm 1)		0.44 [0.19–1.03]	0.29 [0.15–0.56]
number of metastatic sites	(2 or more) vs. 1		2.72 [0.84–8.79]	2.59 [1.24–5.41]
Interaction between arm and number of metastatic sites			0.91 [0.19–4.47]	1.47 [0.50–4.37]
Fatigue		65 (35)
arm a	(arm 2) vs.(arm 1)		0.54 [0.23–1.24]	0.71 [0.40–1.24]
number of metastatic sites	(2 or more) vs. 1		3.27 [0.86–12.42]	3.40 [1.58–7.30]
Interaction between arm and number of metastatic sites			0.58 [0.11–3.17]	0.39 [0.13–1.11]
Pain		65 (34)
arm a	(arm 2) vs.(arm 1)		0.44 [0.18–1.07]	0.57 [0.32–1.03]
number of metastatic sites	(2 or more) vs. 1		3.04 [0.93–9.91]	3.15 [1.51–6.57]
Interaction between arm and number of metastatic sites			0.66 [0.13–3.31]	0.46 [0.16–1.33]

^a Arm 1: gemcitabine alone, Arm 2: gemcitabine + FOLFIRI.3.